Federal newborn screening for CMV aims to prevent hearing loss and developmental delays.

What it does

This bill requires hospitals and health care entities to screen newborns (21 days or younger) for congenital Cytomegalovirus (CMV), a viral infection that can cause hearing loss, developmental delays, and other serious complications. States set screening standards with federal oversight; if a state fails to act within 2 years, a federal advisory committee prescribes standards. The bill authorizes federal grants to states for testing, technical assistance, data systems, provider education, and funds NIH research into CMV screening, diagnostics, and vaccine development.

Why we flagged it

The bill establishes a newborn screening program for a specific infectious disease, funded through federal grants and research appropriations. It is a straightforward public health measure with no private carve-outs or hidden mechanisms.

What the text implies

• States that fail to prescribe standards within 2 years trigger federal advisory committee action, creating a backstop that ensures screening occurs even without state cooperation—a mild federalism shift.
• NIH research funding is drawn from existing appropriations ('amounts available to the Director and not otherwise obligated'), meaning no new budget authority is requested; actual research expansion depends on NIH reprioritization.
• The bill does not mandate screening—it authorizes it—leaving implementation discretion to hospitals and states, which may result in uneven coverage across regions and socioeconomic groups.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Newborns and families benefit from early detection of congenital CMV, which can prevent or reduce hearing loss, developmental delays, and other serious outcomes through timely intervention. The bill imposes no new costs on citizens and funds public health infrastructure and research without restricting access or rights.

Who stands to gain

• state health departments (grant recipients)
• hospitals and health care entities (testing reimbursement via grants)
• diagnostic test manufacturers (increased demand for CMV screening tests)
• research institutions (NIH research funding)

Named in the bill

Health Resources and Services Administration (HRSA), Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), Discretionary Advisory Committee on Heritable Disorders in Newborns and Children, State health departments, Hospitals and health care entities

Where it stands

4 cosponsors: 3 Democrats, 1 Republicans.

• Sep 17, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Sep 17, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 3 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $966,331 in lobbying spend. A filing names 44 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

Richard Blumenthal, the sponsor, reported $110,550 in PAC receipts in the 2026 cycle.

• American Speech-language-hearing Association — $680,000 on 2 filings
• American Academy of Otolaryngology-head and Neck Surgery — $286,331 on 1 filing

Lobbying Disclosure Act filings through Jul 17, 2026. A filing shows who paid to lobby on a bill it names, not what changed.